Matthews Asia Dividend Active ETF ADVE 深 滬
已收盤 08-29 16:00:00 美东时间
36.9162
-0.190
-0.51%
華盛通- 最 高36.9162
- 今 開37.1067
- 成交量 59股
- 最 低 36.9162
- 昨 收 37.1067
- 總市值 369.16万
- 52周最高 37.3604
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 26.8281
- 委 比 0.00%
- 總股本 10.00万
- 歷史最高 37.3604
- 量 比 0.11
- 振 幅 0.00%
- 歷史最低 26.2353
- 每 手 1
- 風險率 1.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tom Lee's Fundstrat Capital Files Preliminary Prospectus for Two New ETFs
NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Fundstrat Capital announced that it has filed a preliminary prospectus with the U.S. Securities and Exchange Commission ("SEC") for two new exchange-t...
08-25 19:30
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical compa...
07-02 20:00
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nas...
06-17 20:08
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today anno...
06-09 19:00
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New Engla...
06-02 20:04
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN, June 2, 2025 /PRNewswire/...
06-02 19:00
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovati...
05-27 14:00
Chimeric Therapeutics Reports Promising Results in ADVENT-AML Trial
Chimeric Therapeutics Ltd. ( ($AU:CHM) ) just unveiled an announcement. Chimeri...
05-15 11:27
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif., April 11, 20...
04-11 21:00
G'DAY, CARNIVAL ADVENTURE AND CARNIVAL ENCOUNTER! TWO SHIPS OFFICIALLY JOIN CARNIVAL FLEET IN AUSTRALIA
Carnival Cruise Line is Now the Leading Cruise Operator in Australia as Global Fleet Grows to Record 29 Ships SYDNEY, March 28, 2025 /PRNewswire/ -- Marking an exciting new chapter for Carni...
03-28 21:00
